EMEA-002066-PIP02-20

Active substance

talazoparib

Decision number

P/130/2021

Pharmaceutical form(s)

Route(s) of administration

Oral use

Decision type

W: decision granting a waiver in all age groups for all conditions or indications

Invented name	Talzenna
Active substance	talazoparib
Therapeutic area	Oncology
Decision number	P/130/2021
PIP number	EMEA-002066-PIP02-20
Pharmaceutical form(s)	Capsule, hard Capsule, soft
Condition(s) / indication(s)	Treatment of breast malignant neoplasms Treatment of prostate malignant neoplasms
Route(s) of administration	Oral use
Contact for public enquiries	Pfizer Europe MA EEIG Tel. +44 (0)1304 646 607 E-mail: pip_enquiries@pfizer.com
Decision type	W: decision granting a waiver in all age groups for all conditions or indications